145 related articles for article (PubMed ID: 26100916)
1. In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions.
Delaunay-Lemarie C; Vincourt JB; Marie B; Battaglia-Hsu SF; Etienne S; Sirveaux F; Nguyen Thi PL; Magdalou J; Vignaud JM; Gauchotte G
Virchows Arch; 2015 Sep; 467(3):329-37. PubMed ID: 26100916
[TBL] [Abstract][Full Text] [Related]
2. C-propeptides of procollagens I alpha 1 and II that differentially accumulate in enchondromas versus chondrosarcomas regulate tumor cell survival and migration.
Vincourt JB; Etienne S; Cottet J; Delaunay C; Malanda CB; Lionneton F; Sirveaux F; Netter P; Plénat F; Mainard D; Vignaud JM; Magdalou J
Cancer Res; 2010 Jun; 70(11):4739-48. PubMed ID: 20460531
[TBL] [Abstract][Full Text] [Related]
3. Vascular pattern in enchondroma and chondrosarcoma: clinical and immunohistologic study.
Cintra FF; Etchebehere M; Gonçalves JC; Cassone AE; Amstalden EM
Appl Immunohistochem Mol Morphol; 2014 Sep; 22(8):600-5. PubMed ID: 24897071
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
[TBL] [Abstract][Full Text] [Related]
5. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
6. Differentiation and proliferative activity in benign and malignant cartilage tumors of bone.
Hasegawa T; Seki K; Yang P; Hirose T; Hizawa K; Wada T; Wakabayashi J
Hum Pathol; 1995 Aug; 26(8):838-45. PubMed ID: 7543439
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for diffusion-weighted MRI (DWI) in the diagnosis of central cartilage tumors?
Douis H; Jeys L; Grimer R; Vaiyapuri S; Davies AM
Skeletal Radiol; 2015 Jul; 44(7):963-9. PubMed ID: 25744812
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas.
Grifone TJ; Haupt HM; Podolski V; Brooks JJ
Int J Surg Pathol; 2008 Jan; 16(1):31-7. PubMed ID: 18203781
[TBL] [Abstract][Full Text] [Related]
9. PAS inclusions, immunoreactive tenascin and proliferative activity in low-grade chondrosarcomas.
Ranty ML; Michot C; Le Pessot F; Hellot MF; Biga N; Dujardin FH; Simonet J; Billerey C; Metayer J
Pathol Res Pract; 2003; 199(1):29-34. PubMed ID: 12650515
[TBL] [Abstract][Full Text] [Related]
10. Expression of connective tissue growth factor in cartilaginous tumors.
Shakunaga T; Ozaki T; Ohara N; Asaumi K; Doi T; Nishida K; Kawai A; Nakanishi T; Takigawa M; Inoue H
Cancer; 2000 Oct; 89(7):1466-73. PubMed ID: 11013359
[TBL] [Abstract][Full Text] [Related]
11. Radiographic Enchondroma Surveillance: Assessing Clinical Outcomes and Costs Effectiveness.
Akoh CC; Craig E; Troester AM; Miller BJ
Iowa Orthop J; 2019; 39(1):185-193. PubMed ID: 31413693
[TBL] [Abstract][Full Text] [Related]
12. Outcome of conservative and surgical treatment of enchondromas and atypical cartilaginous tumors of the long bones: retrospective analysis of 228 patients.
Omlor GW; Lohnherr V; Lange J; Gantz S; Mechtersheimer G; Merle C; Raiss P; Fellenberg J; Lehner B
BMC Musculoskelet Disord; 2019 Mar; 20(1):134. PubMed ID: 30922289
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
[TBL] [Abstract][Full Text] [Related]
14. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors.
Amling M; Pösl M; Hentz MW; Priemel M; Delling G
Verh Dtsch Ges Pathol; 1998; 82():160-9. PubMed ID: 10095428
[TBL] [Abstract][Full Text] [Related]
15. Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors.
Helfenstein A; Frahm SO; Krams M; Drescher W; Parwaresch R; Hassenpflug J
Am J Clin Pathol; 2004 Dec; 122(6):912-8. PubMed ID: 15539383
[TBL] [Abstract][Full Text] [Related]
16. Expression of leukemia inhibitory factor by cartilage-forming tumors of bone: an immunohistochemical study.
Gouin F; Moreau A; Couillaud S; Guicheux J; Passuti N; Godard A; Heymann D
J Orthop Res; 1999 Mar; 17(2):301-5. PubMed ID: 10221849
[TBL] [Abstract][Full Text] [Related]
17. Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma.
Shooshtarizadeh T; Nazeri A; Zare-Mirzaie A; Movahedinia S
Pathol Res Pract; 2016 Apr; 212(4):335-9. PubMed ID: 26948096
[TBL] [Abstract][Full Text] [Related]
18. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
Rozeman LB; Hameetman L; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Pathol; 2005 Mar; 205(4):476-82. PubMed ID: 15685701
[TBL] [Abstract][Full Text] [Related]
19. [Cartilage tumors of the skeleton].
Jundt G; Baumhoer D
Pathologe; 2008 Nov; 29 Suppl 2():223-31. PubMed ID: 18820927
[TBL] [Abstract][Full Text] [Related]
20. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors.
Eefting D; Schrage YM; Geirnaerdt MJ; Le Cessie S; Taminiau AH; Bovée JV; Hogendoorn PC;
Am J Surg Pathol; 2009 Jan; 33(1):50-7. PubMed ID: 18852676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
